Evidence map›Paper›PMID 24873859›Full record

ArticleStem cells translational medicine2014

A multiplex high-throughput gene expression assay to simultaneously detect disease and functional markers in induced pluripotent stem cell-derived retinal pigment epithelium.

Marc Ferrer, Barbara Corneo, Janine Davis, Qin Wan, Kiyoharu Joshua Miyagishima, Rebecca King, Arvydas Maminishkis, Juan Marugan, Ruchi Sharma, Michael Shure and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Role of In Vitro Models for Development of Ophthalmic Delivery Systems.Critical reviews in therapeutic drug carrier systems · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. A new immunodeficient retinal dystrophic rat model for transplantation studies using human-derived cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Marc FerrerNIH Center for Advancing Translational Sciences, NIH, Bethesda, MD, USA.
Barbara CorneoNeural Stem Cell Institute, Rennselaer, New York, NY, USA.
Janine DavisUnit on Ocular and Stem Cell Translational Research, National Eye Institute, NIH, Bethesda, MD, USA.
Qin WanSection on Epithelial and Retinal Physiology and Disease, National Eye Institute, NIH, Bethesda, MD, USA.
Kiyoharu Joshua MiyagishimaSection on Epithelial and Retinal Physiology and Disease, National Eye Insitute, NIH, Bethesda, MD, USA.
Rebecca KingNIH Center for Advancing Translational Sciences, NIH, Bethesda, MD, USA.
Arvydas MaminishkisSection on Epithelial and Retinal Physiology and Disease, National Eye Institute, NIH, Bethesda, MD, USA.
Juan MaruganNIH Center for Advancing Translational Sciences, NIH, Bethesda, MD, USA.
Ruchi SharmaUnit on Ocular and Stem Cell Translational Research, National Eye Institute, NIH, Bethesda, MD, USA.
Michael ShureAffymetrix, Santa Clara, CA, USA.
Sally TempleNeural Stem Cell Institute, Rensselaer, New York, NY, USA.
Sheldon MillerSection on Epithelial and Retinal Physiology, National Eye Institute, NIH, Bethesda, MD, USA.
Kapil BhartiUnit on Ocular and Stem Cell Translational Research, National Eye Institute, Bethesda, MD, USA. kapilbharti@nei.nih.gov
National Eye Institute · USNational Center for Advancing Translational Sciences · USNeural Stem Cell Institute · US

Funding

NIH Chemical Genomics CenterZIBTR000004 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI MCKEW, JOHN · 2012 to 2014
$52.3M
Developing patient-specific iPS cell derived RPE disease modelsZIAEY000532 · NEI · NATIONAL EYE INSTITUTE · PI BHARTI, KAPIL · 2013 to 2025
$22.0M
Human Retinal Pigment Epithelial PhysiologyZIAEY000419 · NEI · NATIONAL EYE INSTITUTE · PI SCHNEEWEIS, DAVID · 2009 to 2020
$12.0M
NIMH NIH HHS U54 MH084681
6 · The paper itself

Abstract

There is continuing interest in the development of lineage-specific cells from induced pluripotent stem (iPS) cells for use in cell therapies and drug discovery. Although in most cases differentiated cells show features of the desired lineage, they retain fetal gene expression and do not fully mature into "adult-like" cells. Such cells may not serve as an effective therapy because, once implanted, immature cells pose the risk of uncontrolled growth. Therefore, there is a need to optimize lineage-specific stem cell differentiation protocols to produce cells that no longer express fetal genes and have attained "adult-like" phenotypes. Toward that goal, it is critical to develop assays that simultaneously measure cell function and disease markers in high-throughput format. Here, we use a multiplex high-throughput gene expression assay that simultaneously detects endogenous expression of multiple developmental, functional, and disease markers in iPS cell-derived retinal pigment epithelium (RPE). We optimized protocols to differentiate iPS cell-derived RPE that was then grown in 96- and 384-well plates. As a proof of principle, we demonstrate differential expression of eight genes in iPS cells, iPS cell-derived RPE at two different differentiation stages, and primary human RPE using this multiplex assay. The data obtained from the multiplex gene expression assay are significantly correlated with standard quantitative reverse transcription-polymerase chain reaction-based measurements, confirming the ability of this high-throughput assay to measure relevant gene expression changes. This assay provides the basis to screen for compounds that improve RPE function and maturation and target disease pathways, thus providing the basis for effective treatments of several retinal degenerative diseases.

Indexed as

Multiplex Polymerase Chain ReactionCell DifferentiationCell LineageCell ProliferationCells, CulturedDrug DiscoveryEpithelial CellsGene Expression ProfilingGene Expression RegulationGenetic MarkersGenetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingHumansInduced Pluripotent Stem CellsLimit of DetectionPhenotypeGenetic MarkersGene expressionInduced pluripotencyiPSReprogrammingRetinaRetinal pigmented epitheliumStem cell

Identifiers

PMID24873859
PMCPMC4116245
OpenAlexW2144635836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.